Sponsored
Novo Nordisk launches Wegovy in India, targets obesity treatment market, offers semaglutide-based weekly injection
Posted
Novo Nordisk has launched Wegovy in India, an anti-obesity drug aimed at managing weight and reducing cardiovascular risks. Priced between Rs 17,345 and Rs 26,050 per month, the injectable drug targets India's large obese population. The company aims to create awareness and collaborate with stakeholders to combat obesity, citing its significant impact on India's GDP.
Search
Categories
- National
- International
- Business
- Technology
- Health
- Education
- Sports
- Entertainment
- Travel
- Environment
- Science
- Law
- Agriculture
- Real Estate
- Opinion
- Religion
- Weather
- Automotive
- Social Issues
- Culture
- Sci-Fi & Future
Read More
White House disputes intelligence report downplaying impact of Iran nuclear strikes
WASHINGTON DC: The White House has rejected a leaked U.S. intelligence assessment suggesting that...
Widespread rain likely across hilly regions today
KATHMANDU: As monsoon conditions persist across Nepal, the Department of Hydrology and...